{
    "eid": "2-s2.0-84908133944",
    "title": "Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial",
    "cover-date": "2014-10-01",
    "subject-areas": [
        {
            "$": "Oncology",
            "@code": "2730"
        }
    ],
    "keywords": [],
    "authors": [
        "Jes\u00fas F. San-Miguel"
    ],
    "citedby-count": 681,
    "ref-count": 28,
    "ref-list": [
        "Improved survival in multiple myeloma and the impact of novel therapies",
        "Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma",
        "Clinical practice guidelines in oncology, multiple myeloma",
        "Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma",
        "Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): A multicentre, randomised, double-blind study",
        "Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges",
        "Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma",
        "In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma",
        "Aggresome induction by proteasome inhibitor bortezomib and \u03b1-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells",
        "Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma",
        "PANORAMA 2: Panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma",
        "A phase 2 study of Bortezomib in relapsed, refractory myeloma",
        "Bortezomib or high-dose dexamethasone for relapsed multiple myeloma",
        "Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma",
        "Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: Combination therapy improves time to progression",
        "Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation",
        "Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study",
        "Association of response endpoints with survival outcomes in multiple myeloma",
        "Blood (ASH Annual Meeting Abstracts)",
        "Efficacy and safety of once-weekly bortezomib in multiple myeloma patients",
        "International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation",
        "European myeloma network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma",
        "Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma",
        "Superiority of the triple combination of bortezomib-thalidomide- dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: The MMVAR/IFM 2005-04 randomized phase III trial from the chronic leukemia working party of the European Group for blood and marrow transplantation",
        "Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America",
        "Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma",
        "Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial",
        "A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma"
    ],
    "affiliation": [
        {
            "affiliation-city": "Hwasun-gun",
            "affilname": "Chonnam National University Hwasun Hospital",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Seongnam",
            "affilname": "Gachon University",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Ramathibodi Hospital",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Siriraj Hospital",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "London",
            "affilname": "UCL Cancer Institute",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Valencia",
            "affilname": "Universidad Cat\u00f3lica de Valencia San Vicente M\u00e1rtir",
            "affiliation-country": "Spain"
        },
        {
            "affiliation-city": "Tianjin",
            "affilname": "Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Warsaw",
            "affilname": "Institute of Haematology and Transfusion Medicine, Warsaw",
            "affiliation-country": "Poland"
        },
        {
            "affiliation-city": "Rome",
            "affilname": "Ospedale S. Spirito",
            "affiliation-country": "Italy"
        },
        {
            "affiliation-city": "Beijing",
            "affilname": "Beijing Chao-Yang Hospital, Capital Medical University",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Warsaw",
            "affilname": "Medical University of Warsaw",
            "affiliation-country": "Poland"
        },
        {
            "affiliation-city": "Athens",
            "affilname": "School of Medicine",
            "affiliation-country": "Greece"
        },
        {
            "affiliation-city": "Alexandria",
            "affilname": "Alexandria University",
            "affiliation-country": "Egypt"
        },
        {
            "affiliation-city": "Wurzburg",
            "affilname": "Universit\u00e4tsklinikum W\u00fcrzburg",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Taipei",
            "affilname": "Chang Gung Memorial Hospital",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Gothenburg",
            "affilname": "Sahlgrenska Universitetssjukhuset",
            "affiliation-country": "Sweden"
        },
        {
            "affiliation-city": "Copenhagen",
            "affilname": "K\u00f8benhavns Universitet",
            "affiliation-country": "Denmark"
        },
        {
            "affiliation-city": "Milan",
            "affilname": "Universit\u00e0 degli Studi di Milano",
            "affiliation-country": "Italy"
        },
        {
            "affiliation-city": "Barcelona",
            "affilname": "Hospital Cl\u00ednic de Barcelona",
            "affiliation-country": "Spain"
        },
        {
            "affiliation-city": "Salamanca",
            "affilname": "Hospital Cl\u00ednico Universitario de Salamanca",
            "affiliation-country": "Spain"
        },
        {
            "affiliation-city": "Nantes",
            "affilname": "CHU de Nantes",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Saratov",
            "affilname": "Saratov State Medical University named after V. I. Razumovsky",
            "affiliation-country": "Russian Federation"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Seoul",
            "affilname": "Seoul National University Hospital",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Pamplona",
            "affilname": "Cl\u00ednica Universidad de Navarra",
            "affiliation-country": "Spain"
        },
        {
            "affiliation-city": "Stockholm",
            "affilname": "Karolinska Universitetssjukhuset",
            "affiliation-country": "Sweden"
        },
        {
            "affiliation-city": "Singapore City",
            "affilname": "Singapore General Hospital",
            "affiliation-country": "Singapore"
        },
        {
            "affiliation-city": "Sao Paulo",
            "affilname": "Universidade Federal de S\u00e3o Paulo",
            "affiliation-country": "Brazil"
        },
        {
            "affiliation-city": "Boston",
            "affilname": "Dana-Farber Cancer Institute",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Rueil-Malmaison",
            "affilname": "Novartis Pharma S.A.S.",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Shanghai",
            "affilname": "Changzheng Hospital",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Daegu",
            "affilname": "Kyungpook National University (KNU)",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Ankara",
            "affilname": "Ankara \u00dcniversitesi",
            "affiliation-country": "Turkey"
        },
        {
            "affiliation-city": "Kiel",
            "affilname": "Christian-Albrechts-Universit\u00e4t zu Kiel",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Basel",
            "affilname": "Novartis International AG",
            "affiliation-country": "Switzerland"
        },
        {
            "affiliation-city": "Montreal",
            "affilname": "H\u00f4pital Maisonneuve-Rosemont",
            "affiliation-country": "Canada"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Phramongkutklao College of Medicine",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "London",
            "affilname": "St Bartholomew's Hospital",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Atlanta",
            "affilname": "Emory University",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Halifax",
            "affilname": "QEII Health Sciences Centre",
            "affiliation-country": "Canada"
        },
        {
            "affiliation-city": "Hamburg",
            "affilname": "Asklepios Clinic Altona",
            "affiliation-country": "Germany"
        }
    ],
    "funding": [
        "Novartis Pharmaceuticals Corporation"
    ]
}